Eli Lilly and Company & Nvidia

Eli Lilly and Company: Eli Lilly and Company>>> advanced after positive trial results for its next-generation obesity drug, retatrutide, which showed benefits beyond weight loss.

Nvidia: Nvidia's stronger-than-expected quarterly report and revenue forecast, driven by demand for its AI chips, significantly boosted market sentiment and led to a rally in technology stocks across Asia and Wall Street. Despite a slight dip in after-hours trading, its performance was a key driver of the overall market gains.

Eli Lilly and Company: Eli Lilly and Company is one of the healthcare leaders whose contracts were added to Phemex's TradFi ecosystem, making its assets available for 24/7 trading to Phemex users.

Nvidia: Nvidia is an existing high-demand asset already available on Phemex, and its inclusion in the expanded TradFi offering reinforces its accessibility for users.

Eli Lilly and Company: Eli Lilly and Company is mentioned as one of the companies that SpaceX's valuation will surpass, emphasizing the magnitude of SpaceX's market entry.

Nvidia: Nvidia is mentioned as a benchmark for market valuation, currently the world's most valuable public company, providing context for SpaceX's potential market value.

Nvidia: Nvidia announced plans to produce up to $500 billion of AI infrastructure in the US, marking a significant expansion of its domestic manufacturing capabilities and strengthening its supply chain. This move is expected to boost its market position and meet growing demand for AI chips.